# Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

> **NCT00826280** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 347 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** regadenoson
- **DRUG:** overencapsulated caffeine
- **RADIATION:** technetium
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00826280
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-24
- **Primary completion:** 2010-07-15
- **Final completion:** 2010-07-15
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826280, "Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00826280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*